AbbVie, a global biopharmaceutical company, announced that the Russian Ministry of Health approved Venclexta (venetoclax), a drug, for oral administration. The drug is a potent selective inhibitor of antiapoptotic protein of B-cell lymphoma (BCL-2).
Venclexta is recommended as monotherapy for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene in adult patients, when the treatment with B-cell receptor signaling pathway inhibitors is not appropriate or did not show expected outcome, and without 17p deletion or mutations of the TP53 gene in adult patients, who did not respond to chemoimmunotherapy and treatment with B-cell receptor signaling pathway inhibitors.
“The therapy of recurrent and/or refractory chronic lymphocytic leukemia is a complex issue in modern oncologic hematology,” said Irina Poddubnaya, Candidate of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Vice-Rector for Academic Affairs and International Cooperation, Head of the Department of Oncology of the Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. “The use of venetoclax allows to treat patients, who have been already treated unsuccessfully with all existing therapeutic options. New therapy does not only increase overall life expectancy of patients, but it also improves the quality of life. Undeniably, this is a valuable additional characteristic of the drug and is undoubtedly of great importance, as CLL becomes increasingly common among working-age adults in Russia.”